BC Innovations | Feb 12, 2019
Distillery Therapeutics


INDICATION: Depression; neurology In silico , cell culture and rat studies identified a methanamine-based agonist of 5-HT1A receptor that could help treat depression and other neuropsychiatric diseases. Chemical synthesis, cell-based screening of methanamine analogs in binding...
BC Innovations | Oct 22, 2015
Distillery Therapeutics

Therapeutics: MEK

Neurology INDICATION: Anxiety Zebrafish studies suggest MEK inhibitors could help treat anxiety caused by overactive cAMP signaling. In zebrafish larvae, a phosphodiesterase-4 (PDE-4) inhibitor promoted cAMP signaling and induced anxiety-like behaviors. Screening of 80 kinase...
BioCentury | Feb 7, 2011
Product Development

Keep It Simple

Genaissance Pharmaceuticals Inc. thought it would leverage its pharmacogenomics expertise in 2004 when it acquired Viibryd vilazodone , a compound that had failed five Phase II trials for depression. But the problem with Viibryd turned out...
BC Innovations | Oct 14, 2010
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Rett syndrome Serotonin (5-HT1A) receptor; solute carrier family 6 neurotransmitter transporter GABA member 1 (SLC6A1; GAT1) Studies in mice suggest that...
BC Innovations | Oct 7, 2010
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Pain; neurology Serotonin (5-HT1A) receptor A study in mice identified pyridylmethylamine-based 5-HT1A receptor agonists that could help treat pain. In...
BC Week In Review | Aug 3, 2009
Clinical News

BCI-952: Phase II data

A modified intent-to-treat (mITT) analysis of 134 patients in a double-blind, U.S. Phase II trial showed that BCI-952 met the co-primary endpoint of significantly improving mean CGI-I score at week 6 compared with placebo (p=0.046),...
BC Extra | Jul 28, 2009
Clinical News

BrainCells reports BCI-952 data

BrainCells Inc. (San Diego, Calif.) reported mixed results from a Phase II trial of BCI-952 to treat major depressive disorder (MDD). A modified intent-to-treat (ITT) analysis showed the combination of low-dose buspirone and melatonin met...
BioCentury | Jun 19, 2006
Product Development

More is less in CNS

Running clinical trials can be complicated when some of the disease symptoms a compound is designed to treat are also side effects of the compound. MediciNova Inc. ran into just such a conundrum with its...
BC Week In Review | Mar 27, 2006
Clinical News

Celexa citalopram: Phase IV data

Data from the Phase IV STAR*D study in 1,439 evaluable patients, with nonpsychotic major depressive disorder who had no remission of symptoms with citalopram treatment or could not tolerate citalopram, showed that both alternate treatments...
BC Extra | Mar 10, 2003
Financial News

BMY shifting R&D spend, reports earnings

Bristol-Myers (BMY) said on a conference call Monday that it will not grow its R&D budget this year and it will shift a significant portion of its R&D spend to later-stage from discovery programs. A...
Items per page:
1 - 10 of 30